During the 2025 OASIS 4 trial looking at the effects of oral semaglutide on people with overweight or obesity, it was shown that patients on average lost 17% of their starting body weight while on Wegovy tablets
Since then, the approved label has been updated several times
This is why most medications delivered through standard transdermal patches are small, lipophilic compounds such as nicotine or certain hormones
Abdelsameea, A
Satiety, clinical adiposity - liraglutide evidence in individuals w, without diabetes study g: Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials
It works by enhancing satiety signals in the brain, helping individuals feel full sooner and reduce overall calorie intake, which supports gradual, medically supervised weight reduction